Search details
1.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30755741
2.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Article
in English
| MEDLINE | ID: mdl-29420467
3.
Neratinib augments the lethality of [regorafenib + sildenafil].
J Cell Physiol
; 234(4): 4874-4887, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30203445
4.
Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations.
Breast Cancer Res Treat
; 174(1): 55-63, 2019 Feb.
Article
in English
| MEDLINE | ID: mdl-30456437
5.
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Br J Clin Pharmacol
; 85(3): 530-539, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30428505
6.
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Breast Cancer Res
; 20(1): 44, 2018 06 08.
Article
in English
| MEDLINE | ID: mdl-29880014
7.
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
Cancer Cell
; 37(2): 183-199.e5, 2020 02 10.
Article
in English
| MEDLINE | ID: mdl-31978326
8.
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Clin Cancer Res
; 14(8): 2465-75, 2008 Apr 15.
Article
in English
| MEDLINE | ID: mdl-18413839
9.
Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.
Oncotarget
; 10(49): 5120-5122, 2019 Aug 20.
Article
in English
| MEDLINE | ID: mdl-31489122
10.
Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
Cancer Biol Ther
; 20(2): 157-168, 2019.
Article
in English
| MEDLINE | ID: mdl-30183517
11.
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial.
Clin Cancer Res
; 25(2): 771-783, 2019 01 15.
Article
in English
| MEDLINE | ID: mdl-30274983
12.
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.
Clin Cancer Res
; 25(1): 277-289, 2019 01 01.
Article
in English
| MEDLINE | ID: mdl-30314968
13.
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Cancer Biol Ther
; 19(3): 239-247, 2018 03 04.
Article
in English
| MEDLINE | ID: mdl-29333953
14.
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Cancer Biol Ther
; 19(6): 525-533, 2018 06 03.
Article
in English
| MEDLINE | ID: mdl-29405820
15.
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Cancer Biol Ther
; 19(2): 132-137, 2018 02 01.
Article
in English
| MEDLINE | ID: mdl-29219657
16.
[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.
Oncotarget
; 9(5): 6062-6074, 2018 Jan 19.
Article
in English
| MEDLINE | ID: mdl-29464055
17.
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Sci Signal
; 11(551)2018 10 09.
Article
in English
| MEDLINE | ID: mdl-30301790
18.
HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.
Oncotarget
; 8(52): 90262-90277, 2017 Oct 27.
Article
in English
| MEDLINE | ID: mdl-29163826
19.
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Cancer Discov
; 7(6): 575-585, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28274957
20.
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
Cancer Cell
; 37(2): 258-259, 2020 Feb 10.
Article
in English
| MEDLINE | ID: mdl-32049049